

## Erratum

---

### Vol. 72, No. RR-2

In the *MMWR* Recommendations and Reports, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season,” on page 15, in the first paragraph, the second sentence should have read, “Examples include AS01B (in Shingrix, recombinant zoster subunit vaccine) (146), AS01E (in **Arexvy**, respiratory syncytial virus vaccine) (147) MF59 (in Flud Quadivalent [aIV4]) (56), and cytosine phosphoguanine oligodeoxynucleotide (in Hepelisav-B, a recombinant hepatitis B surface antigen vaccine) (148).” In addition, on page 25, reference 147 should have read, “**Arexvy** [Package insert]. Durham, NC: GlaxoSmithKline; 2023.”